US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US5102785A
(en)
|
1987-09-28 |
1992-04-07 |
E. I. Du Pont De Nemours And Company |
Method of gene mapping
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
CA2088258C
(en)
|
1990-07-27 |
2004-09-14 |
Phillip Dan Cook |
Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
EP1331011A3
(de)
|
1991-10-24 |
2003-12-17 |
Isis Pharmaceuticals, Inc. |
Derivatisierte Oligonukleotide mit verbessertem Aufnahmevermögen.
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
DE637965T1
(de)
|
1991-11-26 |
1995-12-14 |
Gilead Sciences Inc |
Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen.
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
WO1994013303A1
(en)
|
1992-12-14 |
1994-06-23 |
Start Technology Partnership |
Administration of oligonucleotides antisense to dopamine receptor mrna for diagnosis and treatment of neurological pathologies
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
US5981279A
(en)
|
1995-11-09 |
1999-11-09 |
Allegheny University Of The Health Sciences |
Compositions and methods to regulate calmodulin gene expression, and uses thereof for influencing cell growth and differentiation
|
AU2582197A
(en)
|
1996-03-15 |
1997-10-01 |
Start Technology Partnership |
Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
US5932557A
(en)
|
1997-08-12 |
1999-08-03 |
Mustafa; S. Jamal |
Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
AU9063398A
(en)
|
1997-09-12 |
1999-04-05 |
Exiqon A/S |
Oligonucleotide analogues
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
AU757724B2
(en)
|
1998-05-26 |
2003-03-06 |
Icn Pharmaceuticals, Inc. |
Novel nucleosides having bicyclic sugar moiety
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
ES2257051T3
(es)
|
1998-05-27 |
2006-07-16 |
Avigen, Inc. |
Administracion potenciada por conveccion de vectores aav que codifican aadc.
|
CA2333857A1
(en)
|
1998-07-13 |
2000-01-20 |
Merck & Co., Inc. |
Growth hormone secretagogue related receptors and nucleic acids
|
JP2002528509A
(ja)
|
1998-11-05 |
2002-09-03 |
トーマス・ジェファーソン・ユニバーシティ |
オリゴヌクレオチドを用いるパーキンソン病の治療
|
US20040226056A1
(en)
|
1998-12-22 |
2004-11-11 |
Myriad Genetics, Incorporated |
Compositions and methods for treating neurological disorders and diseases
|
WO2000037483A1
(en)
|
1998-12-22 |
2000-06-29 |
Myriad Genetics, Inc. |
Protein-protein interactions in neurodegenerative disorders
|
TR200604211T1
(tr)
|
1999-02-12 |
2007-02-21 |
Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited |
Yeni nükleosid ve oligonükleotid analoglarıYeni nükleosid ve oligonükleotid analogları
|
EP1178999B1
(de)
|
1999-05-04 |
2007-03-14 |
Santaris Pharma A/S |
L-ribo-lna analoge
|
AU5081200A
(en)
|
1999-05-04 |
2000-11-17 |
Aventis Pharma S.A. |
Use of inducible no-synthase antisense oligonucleotides for preventing and treating cerebral ischemia
|
US6525191B1
(en)
|
1999-05-11 |
2003-02-25 |
Kanda S. Ramasamy |
Conformationally constrained L-nucleosides
|
EP1238069A2
(de)
|
1999-07-15 |
2002-09-11 |
McGill University |
Antisense oligonucleotiden für mglur1
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
AU2001233114A1
(en)
|
2000-02-04 |
2001-08-14 |
Aeomica, Inc. |
Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
|
AU2001250572A1
(en)
|
2000-04-07 |
2001-10-23 |
Epigenomics Ag |
Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
|
US20030032791A1
(en)
|
2000-06-26 |
2003-02-13 |
Alan Robertson Scott |
Novel melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate
|
US6277640B1
(en)
|
2000-07-31 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Her-3 expression
|
US20030060438A1
(en)
|
2000-08-18 |
2003-03-27 |
Henry James L. |
Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof
|
US20020119927A1
(en)
|
2000-10-17 |
2002-08-29 |
Myriad Genetics, Inc. |
Protein-protein interactions in neurodegenerative diseases
|
US20020115606A1
(en)
|
2000-10-17 |
2002-08-22 |
Myriad Genetics, Inc. |
Protein-protein interactions in neurodegenerative diseases
|
US20020151506A1
(en)
|
2000-12-29 |
2002-10-17 |
Castillo Gerardo M. |
Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic AA amyloidosis, and other amyloid disorders
|
EP1499627A2
(de)
|
2001-07-03 |
2005-01-26 |
ISIS Pharmaceuticals, Inc. |
Nukleaseresistente chimäre oligonukleotide
|
US6455308B1
(en)
|
2001-08-01 |
2002-09-24 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of serum amyloid A4 expression
|
WO2003030936A1
(fr)
|
2001-10-02 |
2003-04-17 |
Sumitomo Pharmaceuticals Co., Ltd. |
Medicaments contre des maladies liees au style de vie ou la cibophobie et methode de criblage de ces derniers
|
US20030143738A1
(en)
|
2001-11-08 |
2003-07-31 |
Hiroki Yokota |
Compositions and methods for treating ischemic stroke
|
WO2003055507A1
(fr)
|
2001-12-27 |
2003-07-10 |
Sumitomo Pharmaceuticals Co., Ltd. |
Medicaments contre l'anorexie ou des affections liees au mode de vie et procede de recherche systematique de ces medicaments
|
US20070276034A1
(en)
|
2002-05-31 |
2007-11-29 |
Luke Esposito |
Compounds, compositions and methods for the treatment of synucleinopathies
|
DK2527315T3
(da)
|
2002-05-31 |
2014-06-02 |
Proteotech Inc |
Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
|
WO2008103472A2
(en)
|
2007-02-23 |
2008-08-28 |
Elan Pharmaceuticals, Inc. |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
WO2004041889A2
(en)
|
2002-11-05 |
2004-05-21 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
WO2004044136A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
|
DK2141233T3
(en)
|
2002-11-18 |
2017-01-09 |
Roche Innovation Ct Copenhagen As |
Antisense Design
|
CA2515368A1
(en)
|
2003-02-13 |
2004-08-26 |
Luciano Rossetti |
Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
|
JP2007521792A
(ja)
|
2003-04-16 |
2007-08-09 |
ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ |
異常に切断されたタンパク質を異所性発現する酵母、およびこの用途
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
WO2004106356A1
(en)
|
2003-05-27 |
2004-12-09 |
Syddansk Universitet |
Functionalized nucleotide derivatives
|
EP1481685A1
(de)
|
2003-05-30 |
2004-12-01 |
Aventis Pharma Deutschland GmbH |
Verwendung von PAM
|
US20050032695A1
(en)
|
2003-05-30 |
2005-02-10 |
Aventis Pharma Deutschland Gmbh |
Method for alleviating pain using protein associated with MYC and related compounds, and assays for identifying such compounds
|
EP1481680A1
(de)
|
2003-05-30 |
2004-12-01 |
Aventis Pharma Deutschland GmbH |
Verwendung von S1P
|
WO2005004794A2
(en)
|
2003-06-09 |
2005-01-20 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
US7595306B2
(en)
|
2003-06-09 |
2009-09-29 |
Alnylam Pharmaceuticals Inc |
Method of treating neurodegenerative disease
|
ATE555118T1
(de)
|
2003-08-28 |
2012-05-15 |
Takeshi Imanishi |
Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
US20050074801A1
(en)
|
2003-09-09 |
2005-04-07 |
Monia Brett P. |
Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
|
WO2005027962A1
(en)
|
2003-09-18 |
2005-03-31 |
Isis Pharmaceuticals, Inc. |
4’-thionucleosides and oligomeric compounds
|
ES2387593T3
(es)
|
2004-02-09 |
2012-09-26 |
Ulrich Bogdahn |
Inhibidores de la señalización de TGF-R para el tratamiento de enfermedades del SNC
|
US20050267300A1
(en)
|
2004-04-05 |
2005-12-01 |
Muthiah Manoharan |
Processes and reagents for oligonucleotide synthesis and purification
|
JP2008513507A
(ja)
|
2004-09-17 |
2008-05-01 |
アイシス ファーマシューティカルズ インコーポレイティッド |
増強されたアンチセンスオリゴヌクレオチド
|
DE602005015994D1
(de)
|
2004-09-29 |
2009-09-24 |
Childrens Memorial Hospital |
siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
US20080003570A1
(en)
|
2004-12-22 |
2008-01-03 |
The General Hospital Corporation |
Translation enhancer elements of genes encoding human Tau protein and human alpha-synuclein protein
|
JP4942044B2
(ja)
|
2005-03-03 |
2012-05-30 |
国立大学法人富山大学 |
精神障害関連遺伝子及びその利用
|
US7776538B2
(en)
|
2005-03-03 |
2010-08-17 |
National University Corporation Nagoya University |
Method for diagnosing methamphetamine dependence
|
WO2006099495A2
(en)
|
2005-03-14 |
2006-09-21 |
The Regents Of The University Of California |
Method for preventing or treating pain in a mammal
|
EP2548560B1
(de)
|
2005-06-23 |
2015-06-03 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Modulation der SMN2-Aufspaltung
|
CA2657953A1
(en)
|
2005-07-19 |
2007-01-25 |
University Of Rochester |
Alpha-synuclein antibodies and methods related thereto
|
WO2007030580A2
(en)
|
2005-09-09 |
2007-03-15 |
Oregon Health & Science University |
Neuroprotectants
|
US20100130425A1
(en)
|
2005-09-09 |
2010-05-27 |
Oregon Health & Science University |
Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
|
WO2007030581A2
(en)
|
2005-09-09 |
2007-03-15 |
Oregon Health & Science University |
Neuroprotectants
|
WO2007031091A2
(en)
|
2005-09-15 |
2007-03-22 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of p21 ras expression
|
WO2007031081A2
(en)
|
2005-09-15 |
2007-03-22 |
Santaris Pharma A/S |
RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-Bl00 EXPRESSION
|
EP2545919A1
(de)
|
2005-12-23 |
2013-01-16 |
Link Medicine Corporation |
Behandlung von Synucleinopathien
|
AU2007210038B2
(en)
|
2006-01-26 |
2013-01-10 |
Ionis Pharmaceuticals, Inc. |
Compositions and their uses directed to huntingtin
|
AU2007211080B9
(en)
|
2006-01-27 |
2012-05-03 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
DK2458006T3
(en)
|
2006-05-05 |
2018-08-27 |
Ionis Pharmaceuticals Inc |
Compounds and Methods for Modulating ApoB Expression.
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
WO2007134181A2
(en)
|
2006-05-11 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
GB0610183D0
(en)
|
2006-05-23 |
2006-06-28 |
Isis Innovation |
Treatment of neurodegenerative diseases
|
WO2008003943A2
(en)
|
2006-07-03 |
2008-01-10 |
Zapaloid Limited |
Inhibition of alpha-synuclein aggregation
|
KR20080036902A
(ko)
|
2006-10-24 |
2008-04-29 |
재단법인서울대학교산학협력재단 |
아밀로이드 형성 펩타이드 또는 단백질의 가용성 회합체에선택적으로 작용하는 절단제
|
EP2125852B1
(de)
|
2007-02-15 |
2016-04-06 |
Ionis Pharmaceuticals, Inc. |
5'-substituierte 2'-f-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
|
WO2008113832A2
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
|
EP2170917B1
(de)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
Über n-substituiertes aminomethylen verbrückte, bicyclische nukleinsäureanaloga
|
US8278426B2
(en)
|
2007-06-08 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
ATE538127T1
(de)
|
2007-07-05 |
2012-01-15 |
Isis Pharmaceuticals Inc |
6-disubstituierte bicyclische nukleinsäureanaloga
|
GB0715809D0
(en)
*
|
2007-08-14 |
2007-09-26 |
Univ Leuven Kath |
Alpha synuclein toxicity
|
AU2008286771B2
(en)
|
2007-08-15 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
US8012116B2
(en)
|
2007-08-17 |
2011-09-06 |
Marc Ronald Del Bigio |
Device to reduce brain edema by surface dialysis and cooling
|
AU2008306327B2
(en)
|
2007-10-04 |
2014-05-15 |
Roche Innovation Center Copenhagen A/S |
Micromirs
|
US20090123575A1
(en)
|
2007-11-12 |
2009-05-14 |
Thomas Lake |
Blended Compositions for Treatment of Alzheimer's Disease and Other Amyloidoses
|
US8546556B2
(en)
|
2007-11-21 |
2013-10-01 |
Isis Pharmaceuticals, Inc |
Carbocyclic alpha-L-bicyclic nucleic acid analogs
|
US20090176729A1
(en)
|
2007-12-14 |
2009-07-09 |
Alnylam Pharmaceuticals, Inc. |
Method of treating neurodegenerative disease
|
WO2009124238A1
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
US20100056622A1
(en)
|
2008-08-27 |
2010-03-04 |
Lauterbach Edward C |
Methods of Using Ramelteon to Treat Patients Suffering from a Variety of Neurodegenerative Diseases
|
EP2356129B1
(de)
|
2008-09-24 |
2013-04-03 |
Isis Pharmaceuticals, Inc. |
Substituierte alpha-l-bicyclische nukleoside
|
MX2011006422A
(es)
*
|
2008-12-19 |
2011-09-15 |
Panima Pharmaceuticals Ag |
Autoanticuerpos humanos anti-alfa-sinucleina.
|
CN102448306B
(zh)
|
2009-04-09 |
2014-07-02 |
阿米库斯治疗学公司 |
用于预防和/或治疗中枢神经系统退行性紊乱的方法
|
SI3305302T1
(sl)
|
2009-06-17 |
2018-12-31 |
Biogen Ma Inc. |
Sestave in metode za modulacijo združevanja smn2 pri subjektu
|
US9012421B2
(en)
|
2009-08-06 |
2015-04-21 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
WO2011048125A1
(en)
|
2009-10-20 |
2011-04-28 |
Santaris Pharma A/S |
Oral delivery of therapeutically effective lna oligonucleotides
|
EP2560687B1
(de)
|
2010-04-19 |
2017-05-24 |
Nlife Therapeutics S.L. |
Zusammensetzungen und verfahren zur selektiven abgabe von oligonukleotidmolekülen an spezifische neuronentypen
|
WO2011156202A1
(en)
|
2010-06-08 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US9290759B2
(en)
|
2010-08-25 |
2016-03-22 |
The Trustees Of Columbia University In The City Of New York |
Optimized miRNA constructs
|
JP6126009B2
(ja)
*
|
2010-11-17 |
2017-05-10 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
α−シヌクレイン発現の調節
|
WO2013033230A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
CA2863253A1
(en)
|
2011-09-07 |
2013-03-14 |
Marina Biotech, Inc. |
Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
|
WO2013045652A1
(en)
|
2011-09-28 |
2013-04-04 |
Royal College Of Surgeons In Ireland |
Inhibition of microrna-134 for the treatment of seizure-related disorders and neurologic injuries
|
US9221864B2
(en)
|
2012-04-09 |
2015-12-29 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
US20140155816A1
(en)
|
2012-10-09 |
2014-06-05 |
Eu Sol Biotech Co., Ltd. |
Method for treating brain injury or stroke
|
EP2906255B1
(de)
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense-verbindungen und verwendungen davon
|
RU2653438C2
(ru)
|
2012-11-15 |
2018-05-08 |
Рош Инновейшен Сентер Копенгаген А/С |
Конъюгаты олигонуклеотидов
|
WO2014110291A1
(en)
|
2013-01-09 |
2014-07-17 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of smn2 splicing in a subject
|
DK2951191T3
(en)
|
2013-01-31 |
2019-01-14 |
Ionis Pharmaceuticals Inc |
PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS
|
EP2971010B1
(de)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
|
PE20152002A1
(es)
|
2013-05-01 |
2016-01-21 |
Isis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de ttr y vhb
|
LT3013959T
(lt)
|
2013-06-27 |
2020-03-10 |
Roche Innovation Center Copenhagen A/S |
Priešprasmiai oligomerai ir konjugatai, nukreirti į pcsk9
|
WO2015034928A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3043826A4
(de)
|
2013-09-13 |
2017-05-24 |
Moderna Therapeutics, Inc. |
Polynukleotidzusammensetzungen mit aminosäuren
|
EP3052106A4
(de)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynukleotide zur codierung immunmodulierender polypeptide
|
EP3052521A1
(de)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
|
KR20160062069A
(ko)
|
2013-10-11 |
2016-06-01 |
아이오니스 파마수티컬즈, 인코포레이티드 |
C9orf72 발현을 조절하기 위한 조성물
|
EP3058082A4
(de)
|
2013-10-18 |
2017-04-26 |
ModernaTX, Inc. |
Zusammensetzungen und verfahren zur herbeiführung der toleranz zellulärer systeme
|
EP3076994A4
(de)
|
2013-12-06 |
2017-06-07 |
Modernatx, Inc. |
Gerichtete adaptive impfstoffe
|
US20170002060A1
(en)
|
2014-01-08 |
2017-01-05 |
Moderna Therapeutics, Inc. |
Polynucleotides for the in vivo production of antibodies
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
EP3177732A4
(de)
|
2014-08-08 |
2018-04-25 |
ModernaTX, Inc. |
Zusammensetzungen und verfahren zur behandlung von augenerkrankungen und augenleiden
|
BR112017004056A2
(pt)
|
2014-09-12 |
2017-12-05 |
Biogen Ma Inc |
composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
|
JP2017536366A
(ja)
|
2014-11-19 |
2017-12-07 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Lnaキラルホスホロチオエート
|
CN107709560A
(zh)
|
2015-04-15 |
2018-02-16 |
哈德森医学研究所 |
治疗方法
|
PL3283080T3
(pl)
|
2015-04-16 |
2020-07-27 |
Ionis Pharmaceuticals, Inc. |
Kompozycja do modulowania ekspresji c9orf72
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
US20210052631A1
(en)
|
2015-09-25 |
2021-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
WO2017053999A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
EP3415524A4
(de)
|
2016-01-07 |
2019-09-04 |
Osaka University |
INHIBITOR DER a-SYNUKLEIN-EXPRESSION
|
WO2017189963A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
MA45270A
(fr)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
AR109750A1
(es)
|
2016-09-29 |
2019-01-23 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de tau
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
WO2019009299A1
(ja)
|
2017-07-05 |
2019-01-10 |
国立大学法人大阪大学 |
α-シヌクレイン発現抑制するENAアンチセンスオリゴヌクレオチド
|
WO2019009298A1
(ja)
|
2017-07-05 |
2019-01-10 |
国立大学法人大阪大学 |
α-シヌクレイン発現抑制剤
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
EP3737759A1
(de)
|
2018-01-12 |
2020-11-18 |
Roche Innovation Center Copenhagen A/S |
Alpha-synnuclein-antisense-oligonukleotide und verwendungen davon
|
MX2020007439A
(es)
|
2018-01-12 |
2020-09-14 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido que actuan sobre alfa-sinucleina y usos de estos.
|
MX2020007433A
(es)
|
2018-01-12 |
2020-09-14 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos.
|
WO2019195519A1
(en)
|
2018-04-06 |
2019-10-10 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating antisense activity
|
KR20210008497A
(ko)
|
2018-05-09 |
2021-01-22 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Atxn3 발현 감소용 화합물 및 방법
|
EP3807411A4
(de)
|
2018-06-14 |
2022-08-03 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur verminderung der atxn3-expression
|
PE20210518A1
(es)
|
2018-06-27 |
2021-03-17 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la reduccion de la expresion de lrrk2
|
TW202020154A
(zh)
|
2018-07-25 |
2020-06-01 |
美商Ionis製藥公司 |
用於減少atxn2表現之化合物及方法
|
JP2022500079A
(ja)
|
2018-09-10 |
2022-01-04 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals, Inc. |
Cln3の発現を調節するための化合物及び方法
|
US20220031731A1
(en)
|
2018-09-20 |
2022-02-03 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of lmna expression
|
JP7455831B2
(ja)
|
2018-11-21 |
2024-03-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
プリオン発現を低減するための化合物及び方法
|
JP2022515140A
(ja)
|
2018-12-21 |
2022-02-17 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Pmp22の発現を低減するための化合物及び方法
|
UY38562A
(es)
|
2019-01-29 |
2020-08-31 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de app
|